Programmed death-ligand1 is a determinant of recurrence in alveolar echinococcosis

Objectives: Alveolar echinococcosis (AE) recurrence is one of the major stakes in patients undergoing surgery, the main curative treatment. Preliminary data demonstrated an effect of programmed deathligand1 (PD-L1) inhibitors on AE proliferation in animals. The current study aimed to analyze the prognostic value of PD-L1 expression in tissue samples of patients with AE undergoing surgery.Methods: A cross-sectional study of patients operated for AE between 2002 and 2017 was performed. Patients with recurrence were matched 1: 2 with patients without recurrence. The matching criteria were PNM staging (P = hepatic localization of the parasite, N = extra-hepatic involvement of neighboring organs, and M = absence or presence of metastasis), resection status, preoperative albendazole treatment, and lesion size. PD-L1 immunohistochemistry staining was performed in surgical liver specimens. The expression of PD-L1 was assessed in immune cells. Disease-free survival was calculated using the KaplanMeier method.Results: Among 68 consecutive patients, eight patients with recurrence were matched to 16 patients without recurrence. PD-L1 was overexpressed in patients with recurrence (recurrence: PD-L1 < 1%: one, PD-L1 >1%: seven; no recurrence: PD-L1 < 1%: nine, PD-L1 >1%: seven, P = 0.040). Moreover, patients with lower PD-L1 expression ( < 1%) showed better median disease-free survival (120 months, 95% confidence interval 104-135 vs 74, 95% confidence interval 44-104, P = 0.050).Conclusion: These findings highlight the proof of concept of PD-L1 in AE, but further data on its prognostic importance and the role of immune checkpoint blockade as a promising therapeutical strategy are needed.(c) 2023 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.

Automated summary

This study analyzed the prognostic value of PD-L1 expression in tissue samples of patients with AE undergoing surgery. It found that patients with lower PD-L1 expression had better disease-free survival. These findings highlight the potential importance of PD-L1 in AE and the role of immune checkpoint blockade as a promising therapeutic strategy.